Bluebird Bio – Talk Bio

Actionable Insights Powered by AI

bluebird bio Rebrands as Genetix Biotherapeutics Following Private Equity Buyout

1 month ago talkbio0Tagged Anemia, Sickle Cell, Bluebird Bio, Capital Partners, Carlyle, Cerebral Adrenoleukodystrophy, commercial, David Meek, DKK1 gene, execution, FDA-approved therapies, gene therapy, Genetix Biotherapeutics, Investments, Manufacturing, Private Equity, rebranding, Thalassemia

bluebird bio; Genetix Biotherapeutics; private equity buyout; Carlyle; SK Capital Partners; gene therapy; rebranding; FDA-approved therapies; David Meek; sickle cell disease; β-thalassemia; cerebral adrenoleukodystrophy; commercial execution; manufacturing investment

Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer

7 months ago talkbio0Tagged Ayrmid, Bluebird Bio, Capital, Carlyle, Family Turdidae (organism), gene therapy, High, Twice a day

Ayrmid, Family Turdidae (organism), Twice a day, gene therapy, Carlyle, High, Bluebird Bio, Capital